Fecal microbial signatures show promise for colorectal and pancreatic cancer assessment
· Medical Xpressedited by Swati Mestri, reviewed by Andrew Zinin
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
Gastrointestinal and pancreatobiliary cancers can be difficult to detect early, creating a need for practical, noninvasive approaches for early detection and risk assessment. The gut microbiome has emerged as a potential source of cancer biomarkers, offering practical opportunities for noninvasive testing, as microbial changes can be assessed in fecal samples.
However, using sequencing-based microbiome testing in routine clinical practice remains challenging because of its cost, analytical complexity and need for specialized data analysis. Targeted quantitative PCR (qPCR) could offer a simpler way to translate microbiome signals into accessible testing.
Against this backdrop, a research team led by Associate Professor Tadashi Fujii from the Department of Medical Research on Prebiotics and Probiotics at Fujita Health University in Japan, along with fellow researchers Dr. Hideaki Takahashi, Professor Takumi Tochio, Professor Yoshiki Hirooka and Professor Yohei Doi from the same institute, evaluated six fecal microbial markers and developed disease-specific logistic models for colorectal cancer (CRC) and pancreatic cancer (PC).
Four markers—afb, nan, fsr and 5ar—were selected for the CRC model, while three—but, fsr and saa—were selected for the PC model.
Their findings were published in the journal Bioscience, Biotechnology, and Biochemistry on Sept. 1, 2026.
The researchers assessed how well the models could distinguish cancer from control samples using leave-one-out cross-validation. The CRC model produced an area under the curve (AUC) of 0.824, while the PC model produced an AUC of 0.780.
When the fixed models were applied to related clinical groups, the CRC model showed an AUC of 0.716 for colorectal adenoma. The PC model produced an AUC of 0.804 in an exploratory early PC subgroup and 0.540 when distinguishing pancreatic high-risk individuals without overt cancer from controls.
In a further exploratory comparison, the fecal qPCR score produced an AUC of 0.739 for early PC versus the high-risk group, compared with 0.543 for serum CA19-9. The difference did not reach conventional statistical significance.
"Our findings suggest that a common fecal microbial panel can produce different disease-specific signatures for CRC and PC," Fujii said.
"The results also raise the possibility that fecal qPCR could provide complementary information without invasive sampling."
The study also explored whether the PC score changed during treatment in patients who achieved a partial response to chemotherapy. In this post hoc analysis, the score remained stable in the 1-kestose group but increased in the nonadministration group, whereas CA19-9 decreased in both groups.
Because stool collection is noninvasive, simple and suitable for repeated or home-based sampling, the researchers suggest that this approach could eventually support screening and surveillance. For CRC, regular fecal testing might help identify people who may benefit from colonoscopy, including people with precancerous adenomas.
For PC, repeated testing could potentially help clinicians identify high-risk individuals who may need closer assessment with MRI or endoscopic ultrasound. These applications remain hypothetical and require prospective studies with independent validation.
"Ultimately, we hope this type of testing can become a simple first-step assessment that helps determine which individuals may need further clinical examination and the appropriate timing for follow-up," Fujii said.
"Earlier identification of cancer or precancerous changes could help guide timely intervention, reduce unnecessary invasive testing, and potentially improve outcomes and quality of life."
Overall, the study supports further investigation of targeted fecal qPCR as an exploratory tool for cancer-related risk assessment and surveillance, while larger prospective studies are needed to confirm its accuracy, reproducibility and clinical usefulness.
More information
Tadashi Fujii et al, Disease-specific gut microbial signatures generate model-derived cancer probability scores through targeted fecal qPCR profiling, Bioscience, Biotechnology, and Biochemistry (2026). DOI: 10.1093/bbb/zbag090
Key medical concepts
Colorectal CancerPancreatic Cancer
Clinical categories
OncologyGastroenterologyLaboratory medicine Provided by Fujita Health University Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Fecal microbial signatures show promise for colorectal and pancreatic cancer assessment (2026, September 16) retrieved 16 September 2026 from https://medicalxpress.com/news/2026-09-fecal-microbial-signatures-colorectal-pancreatic.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.